Search - tctmd.com

Displaying 41 - 54 of 54

Sort: Relevancy | Date

Presentation THT 2023

What are the Strengths and Limitations of a Two-Phase (6-Month Intermediate Endpoints & 12-18 Month Mortality and Heart Failure Hospitalization) Trial Design

Presenter: William Abraham

March 20, 2023

News Conference News THT 2022

Xenotransplant of Pig Heart ‘Just Baby Steps,’ Lead Surgeon Says

Yael L. Maxwell

February 07, 2022

News Conference News THT 2022

Cardiogenic Shock’s Origins, Progression Tightly Tied to Mortality

Caitlin E. Cox

February 07, 2022

News Conference News THT 2022

PA Pressure Monitoring Useful Even in Presymptomatic CHF Patients

L.A. McKeown

February 03, 2022

News Conference News THT 2022

Early Positive Signals From RELIEVE-HF Shift Discussion to Atrial Shunt Size

Shelley Wood

February 02, 2022

Presentation THT 2022

Innovation in Heart Failure Trial Designs

Presenter: Ori Ben-Yehuda

February 02, 2022

Presentation THT 2022

Efficacy of Hemodynamic-Guided Heart Failure Management in Patients Enrolled With Elevated Natriuretic Peptide Levels but Without a Recent HF Hospitalization: An Analysis of the GUIDE-HF Trial

Presenter: Akshay Desai

February 02, 2022

Presentation THT 2022

Design and Rationale of the CORCINCH-HF pivotal study

Presenter: Ulrich Jorde

February 01, 2022

News Conference News THT 2022

REDUCE LAP-HF II: Atrial Shunt Device Comes Up Short in HFpEF

Shelley Wood

February 01, 2022

Presentation THT 2022

AMI vs HF-Shock: They Are NOT the Same

Presenter: Navin Kapur

February 01, 2022

Presentation THT 2022

Interstitial Space Fluid / Lymphatics

Presenter: Maxim Itkin

February 01, 2022

Presentation THT 2022

DCD - Donation After Cadiac Death

Presenter: Nader Moazami

February 01, 2022

Presentation THT 2022

Recovered EF Heart Failure -- Physiology, Clinical Implications, and Treatment

Presenter: Douglas Mann

February 01, 2022

Advertisement

What are the Strengths and Limitations of a Two-Phase (6-Month Intermediate Endpoints & 12-18 Month Mortality and Heart Failure Hospitalization) Trial Design

Xenotransplant of Pig Heart ‘Just Baby Steps,’ Lead Surgeon Says

Cardiogenic Shock’s Origins, Progression Tightly Tied to Mortality

PA Pressure Monitoring Useful Even in Presymptomatic CHF Patients

Early Positive Signals From RELIEVE-HF Shift Discussion to Atrial Shunt Size

Innovation in Heart Failure Trial Designs

Efficacy of Hemodynamic-Guided Heart Failure Management in Patients Enrolled With Elevated Natriuretic Peptide Levels but Without a Recent HF Hospitalization: An Analysis of the GUIDE-HF Trial

Design and Rationale of the CORCINCH-HF pivotal study

REDUCE LAP-HF II: Atrial Shunt Device Comes Up Short in HFpEF

AMI vs HF-Shock: They Are NOT the Same

Interstitial Space Fluid / Lymphatics

DCD - Donation After Cadiac Death

Recovered EF Heart Failure -- Physiology, Clinical Implications, and Treatment

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content